Neurocrine Biosciences Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Neurocrine Biosciences ha aumentado sus beneficios a una tasa media anual de 15.9%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 15.5% anual. Los ingresos han ido creciendo a una tasa media de 21.9% al año. La rentabilidad financiera de Neurocrine Biosciences es de 15.5%, y sus márgenes netos son de 18.7%.

Información clave

15.9%

Tasa de crecimiento de los beneficios

14.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	21.9%
Rentabilidad financiera	15.5%
Margen neto	18.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Recent updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Desglose de ingresos y gastos

Cómo gana y gasta dinero Neurocrine Biosciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:NBIX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	1,982	370	888	0
31 Dec 23	1,887	250	888	0
30 Sep 23	1,784	191	852	0
30 Jun 23	1,673	176	834	0
31 Mar 23	1,599	64	795	0
31 Dec 22	1,489	155	753	0
30 Sep 22	1,389	58	726	0
30 Jun 22	1,297	12	695	0
31 Mar 22	1,208	71	655	0
31 Dec 21	1,134	90	583	0
30 Sep 21	1,069	445	533	0
30 Jun 21	1,032	365	491	0
31 Mar 21	1,045	402	445	0
31 Dec 20	1,046	407	433	0
30 Sep 20	1,042	93	428	0
30 Jun 20	1,006	205	400	0
31 Mar 20	887	177	384	0
31 Dec 19	788	37	354	0
30 Sep 19	675	21	322	0
30 Jun 19	605	18	298	0
31 Mar 19	519	-39	278	0
31 Dec 18	451	21	249	0
30 Sep 18	414	10	236	17
30 Jun 18	323	-52	220	32
31 Mar 18	233	-106	200	48
31 Dec 17	162	-143	170	0
30 Sep 17	67	-194	137	90
30 Jun 17	6	-220	111	88
31 Mar 17	0	-200	84	90
31 Dec 16	15	-141	68	58
30 Sep 16	15	-126	53	57
30 Jun 16	15	-123	47	58
31 Mar 16	15	-107	39	52
31 Dec 15	20	-89	32	48
30 Sep 15	20	-79	29	44
30 Jun 15	20	-60	22	37
31 Mar 15	20	-50	19	34
31 Dec 14	0	-61	18	32
30 Sep 14	1	-52	16	29
30 Jun 14	1	-47	15	27
31 Mar 14	2	-46	14	26
31 Dec 13	3	-46	13	25
30 Sep 13	24	-26	13	25
30 Jun 13	33	-18	13	26

Ingresos de calidad: NBIX tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (13.2%) de NBIX son superiores a los del año pasado (10.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NBIX ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 15.9% al año.

Acelerando crecimiento: El crecimiento de los beneficios de NBIX en el último año (477.7%) supera su media de 5 años (15.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de NBIX en el último año (477.7%) superó al de la industria Biotechs -14.4%.

Neurocrine Biosciences Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Recent updates

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Consensus EPS estimates increase by 22%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Consensus EPS estimates fall by 23%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Human Resources Officer notifies of intention to sell stock